ClinicalTrials.gg
RecruitingNCT07584434Updated Jun 8, 2026

A Phase 1, First-in-human Study of VX-433

A Phase 1 interventional study of VX-433 and Placebo in Narcolepsy Type 1 (NT1), sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Planned enrollment
28th of 69
118 · median 93
Started
2026
with 9 others
Phase 1
13 of 85
1 open now
Primary completion
2027-03
later than 4 of 19 live
Registered
82nd of 85
by date

Among the 85 studies in Narcolepsy with a site in United States, this one is the 28th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 13 in phase 1, reaches primary completion later than 4 of the 19 other live ones, and was the 82nd registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.

Read the detailed description

The study is being conducted in healthy participants to evaluate the safety, tolerability, and PK of VX-433 (Parts A and B), as well as potential drug-drug interaction (DDI) between VX-433 and midazolam or bupropion (Part C).

Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Narcolepsy Type 1 (NT1)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m2), inclusive
  • A total body weight of more than (>) 50 kg
  • Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption
  • For female participants: of , pregnant, breastfeeding, or planning to become pregnant or donate ova during the study or within 90 days after last dose of study drug

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD)

    Participants will be randomized to receive a single dose of VX-433.

    Drug: VX-433

  • Placebo comparator
    Part A: Placebo

    Participants will be randomized to receive placebo matched to VX-433.

    Drug: Placebo

  • Experimental
    Part B: Multiple Ascending Dose (MAD)

    Participants will be randomized to receive multiple doses of VX-433.

    Drug: VX-433

  • Placebo comparator
    Part B: Placebo

    Participants will be randomized to receive placebo matched to VX-433.

    Drug: Placebo

  • Experimental
    Part C: Drug Drug Interaction

    Participants will receive a single dose of midazolam and bupropion on Day 1 in Dosing Period 1, followed by VX-433 administration for 17 days (Days 5 through 21) and then midazolam and bupropion on Day 18 in Dosing Period 2. Part C will be open-label.

    Drug: VX-433 · Drug: Midazolam · Drug: Bupropion

Interventions

  • DrugVX-433

    Suspension for Oral Administration

  • DrugPlacebo

    Suspension for Oral Administration

  • Syrup for Oral Administration

  • Capsule for Oral Administration

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 6

  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 18

  3. Part C: Maximum Observed Plasma Concentration (Cmax) of Midazolam in the Absence and Presence of VX-433

    Time frame: From Day 1 up to Day 22

  4. Part C: Maximum Observed Plasma Concentration (Cmax) of Bupropion and Hydroxybupropion in the Absence and Presence of VX-433

    Time frame: From Day 1 up to Day 22

  5. Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in the Absence and Presence of VX-433

    Time frame: From Day 1 up to Day 22

  6. Part C: Area Under the Concentration Versus Time Curve (AUC) of Bupropion and Hydroxybupropion in the Absence and Presence of VX-433

    Time frame: From Day 1 up to Day 22

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of VX-433

    Time frame: From Day 1 up to Day 6

  2. Part B: Maximum Observed Plasma Concentration (Cmax) of VX-433

    Time frame: From Day 1 up to Day 18

  3. Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-433

    Time frame: From Day 1 up to Day 6

  4. Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-433

    Time frame: From Day 1 up to Day 18

  5. Part A: Time Required for Plasma Concentration of VX-433 to Reduce to Half (t1/2)

    Time frame: From Day 1 up to Day 6

  6. Part B: Time Required for Plasma Concentration of VX-433 to Reduce to Half (t1/2)

    Time frame: From Day 1 up to Day 18

  7. Part A: Renal Clearance (CLr) of VX-433

    Time frame: From Day 1 up to Day 2

  8. Part B: Renal Clearance (CLr) of VX-433

    Time frame: From Day 1 up to Day 11

  9. Part A: Amount of VX-433 excreted in Urine

    Time frame: From Day 1 up to Day 2

  10. Part B: Amount of VX-433 excreted in Urine

    Time frame: From Day 1 up to Day 11

  11. Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 29

07

Study locations

1 of 1 sites recruiting
  • ICON - Utah - Salt Lake City Office
    Salt Lake City, Utah 84124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 13 phase 1 interventional studies under Narcolepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's planned 9 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartActual
May 21, 2026
Primary completionEst.
Mar 5, 2027
CompletionEst.
Mar 5, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07584434
Responsible party
Sponsor
First posted
May 13, 2026
Start date
May 21, 2026
Primary completion
Mar 5, 2027 (estimated)
Completion
Mar 5, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion